Zyprexa Rxs Stabilize, But 2006 Gains Largely Driven By Dual-Eligible Switch
Executive Summary
Zyprexa prescription trends are showing signs of stabilization in the U.S., but rebounding sales of Lilly's top-selling drug will be challenged this year as the full-year effect of patient switches from Medicaid to Medicare Part D cycles through in the first quarter, the company said